1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

類似資料

• 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
  著者:: Teichner, Paula, 等
  出版事項: (2019)
• The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans
  著者:: Rosie Mngqibisa, 等
  出版事項: (2025-07-01)
• LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
  著者:: D'Amico, Ronald, 等
  出版事項: (2020)
• Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
  著者:: Cutrell, Amy G., 等
  出版事項: (2021)
• 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study
  著者:: Mills, Anthony, 等
  出版事項: (2020)